Surrounding the topic of innovative drug development, Yeedozencom successfully co-hosted the 4th China Innovative Drug Forum

In the golden autumn of October, also a harvest season, the 4th China Innovative Drug Forum, sponsored by Chinese Journal of New Drugs, was successfully held on October 17-18, 2020. Academician Chen Kaixian served as the President of the Conference. Among other leaders, experts and scholars, Jiao Hong, director of the National Medical Products Administration; Yin Yong, vice mayor of Beijing; Wang Tao, chief reviewer of the CDE attended the Conference. Four sub-forums were held at the conference, namely, new drug R&D and clinical research of TCMs, risks and quality management of clinical trials, Pharmacoeconomics (PE) and Medical Insurance Forum as well as Frontier Forum on biomedicines. As the co-organizer of this forum, Yeedozencom joined hand in hand with its subsidiaries to participate in the conference and share the experience of innovative drug R&D on site.

Moment of Yeedozencom

Dr. Gu Zheming, chief expert on drug metabolism and general manager of Jiangsu Value Pharmaceutical Technology Co., LTD. was invited to attend the meeting and deliver a lecture on “the importance of the human mass balance study for the marketing application of innovative small molecule drugs”. In his speech, Dr. Gu first pointed out that the mass balance is generally carried out with radiolabeled compound, detailed the two purposes of the human mass balance study (see figure below), and explained the importance of the study for the application of innovative drugs with profundity and an easy-to-understand approach. In recent years, innovative small molecule drugs approved and being marketed in China, such as Anlotinib, Pyrotinib, Fruquintinib, Zanubrutinib, etc. have all submitted the results of the human mass balance study. With rich experience, Yeedozencom and Jiangsu Value can assist you in planning and successfully completing the human mass balance study, thus accelerating the approval for marketing of new drugs. 

figure: two purposes of the human mass balance study

Dr. Yang Zhenyu, general manager of Liaoning Yeedo Medical Data Technology Co., Ltd. and chief scientist of Biostatistics of Yeedozencom, shared “the new ideas of new drug R&D and clinical submission under the real world evidence”. Dr. Yang Zhenyu first introduced to the participants the background information on the development of real world research at home and abroad and explained the meaning of three concepts: “real world data”, “real world evidence” and “real world research”. Next, combined with his own practical work, he introduced in detail to the participants the supportive role of real-world evidence in the application of drug regulatory decisions to new drug registrations and marketing, changes in the specifications of drugs already on the market, and chemicals and TCMs such as Fluticasone Propionate Inhaled Aerosol and Ibuprofen Injection. Ultimately, Dr. Yang Zhenyu shared his thoughts on the application of real world data, real world evidence, and real world research to registration decisions.

In recent years, the development of innovative drugs in China is in full momentum. As a CRO service provider with in-depth and compassionate attitude, Yeedozencom is actively engaged in clinical research and registration of innovative drugs and stays committed to providing full life -cycle CRO services for innovative drug enterprises. Yeedozencom has now provided more than 350 IND, registrations and other related services for over 160 customers at home and abroad, with indications including oncology, ophthalmology, cardiovascularology, respiration, urology, etc. The efforts Yeedozencom makes have won wide recognition from customers and its good reputation is reformed in the industry. Looking into the future, Yeedozencom will continue to keep up with the cutting-edge technologies of biomedicine, bear in mind the values of “science, integrity, co-governance and sharing”, and give full play to its advantages of the integrated and comprehensive service platform. Together with its subsidiaries and customers, Yeedozencom will persist in contributing its own efforts to promote the innovative development of China's pharmaceutical industry.